Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer
Phase 3
Withdrawn
- Conditions
- Lung Cancer
- Interventions
- Dietary Supplement: Vitamin E (AT)
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00003599
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
Phase 3
Withdrawn
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00003564
Irofulven in Treating Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00003441
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Amifostine in Treating Patients With Myelodysplastic Syndrome
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00003048
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
Phase 2
Completed
- Conditions
- Metastatic CancerLiver Cancer
- Interventions
- Procedure: Radiofrequency Ablation
- First Posted Date
- 2004-08-20
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT00004136
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Phase 2
Completed
- Conditions
- Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: FilgrastimProcedure: Peripheral Blood Stem Cell Transplantation
- First Posted Date
- 2004-07-30
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00002833
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
Phase 1
Completed
- Conditions
- Leukemia
- Interventions
- Biological: FilgrastimProcedure: Allogeneic Bone Marrow TransplantationProcedure: Peripheral Blood Stem Cell Transplantation
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00002831
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: FilgrastimProcedure: Allogeneic Bone Marrow TransplantationProcedure: Peripheral Blood Stem Cell Transplantation
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00002832
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Myelodysplastic SyndromesLeukemia
- Interventions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00004263
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
Phase 2
Completed
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 95
- Registration Number
- NCT00088218
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath